ALBANY MEDICAL COLLEGE

ALBANY MEDICAL COLLEGE Patent applications

Patent application number

Title

Published

20160123966

CYCLIC-DI-AMP SPECIFIC DETECTION - The present disclosure provides a simple yet fast, cost effective, reliable method for the detection and quantification of cyclic-di-adenosine monophosphate (c-di-AMP) by measuring c-di-AMP binding to a c-di-AMP-binding protein (CabP). A sample is contacted with CabP in the presence of biotin-labeled c-di-AMP. Once binding has reached equilibrium, unbound c-di-AMP is removed and the CabP-bound c-di-AMP is contacted with an enzyme-conjugated biotin-binding protein and a chromogenic substrate to generate a detectable signal. The signal generated correlates to the amount of unlabeled c-di-AMP in the sample.

05-05-2016

20160066964

DEVICE AND METHOD FOR CORRECTING A SPINAL DEFORMITY - A method for correcting a spinal deformity is provided. A spinal implant for correcting a spinal deformity includes a multipoint connector that connects to at least one vertebra of a spine at a plurality of locations and a force directing device that applies a force to the vertebra through the multipoint connector. The force directing device may include a rod which extends generally along an axis of the spine and a force directing member which is adjustably coupled to both the rod and the multipoint connector and which applies a corrective force to the at least one vertebra.

03-10-2016

20160022788

COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISEASES - The present invention provides compositions comprising immunologically effective amounts of one or more autoimmune disease associated antigens or antigenic fragments or derivatives thereof and one or more Th2 promoting adjuvants. The compositions may optionally comprise one or more Th2 promoting TLR2 ligands. The invention further provides methods of treating or preventing an autoimmune disease, such as multiple sclerosis, comprising administering to a subject in need thereof an immunologically-effective amount of an autoimmune disease associated antigen, a Th2 promoting adjuvant and optionally one or more Th2 promoting TLR2 ligands which overall causes re-routing of the harming immune cells to places where they can be of no harm.

01-28-2016

20150030632

FUSION PROTEIN FOR ENHANCING IMMUNOGENICITY OF BACTERIAL ANTIGEN/IMMUNOGEN - Establishment of an effective and uniform vaccine development strategy is key to conquering current and emerging infectious diseases. Despite successes against an array of bacterial agents, current approaches to vaccine development are as diverse as the microbes they target and require adjuvants that often have limited efficacy and/or toxic side effects. As a consequence, vaccine discovery is often slow, inefficient, and unsuccessful in the case of many high priority pathogens. The present disclosure suggests that vaccine generation for bacterial pathogens can be improved by optimizing the efficiency of processing/presentation of a bacterial immunogen via the targeting of immunogen to CR2 and/or TLR2 on APCs. This approach not only yields an adjuvant-free mucosal vaccine against a Category A biothreat agent, but also establishes a novel genetic approach/platform for vaccine development, which is applicable to many other infectious agents, thereby profoundly impacting preventive medicine/public health.

01-29-2015

20140200613

DYNAMIC SPINAL PLATING SYSTEM - Dynamic spinal plating systems that can be placed on the anterior aspect of the spine to aid in spinal fusion and surgical methods for using the dynamic spinal plating systems are disclosed. The dynamic spinal plating systems including a plate and at least one bone attachment mechanism. The plate including a superior end with at least one screw hole, an inferior end, and two lateral sides forming an opening that is transverse by the bone attachment mechanism. The dynamic spinal plating systems also include at least one screw plate with a center screw hole and two passageways that mate with two transverse members of the bone attachment mechanism. When implanted the vertebral stabilization devices may provide a degree of movement in the superior-inferior direction providing for a minimal change in length as the patient moves and as vertebral body height decreases.

07-17-2014

20130059794

ALPHA-FETOPROTEIN "RING AND TAIL" PEPTIDES - The invention relates to compounds that are analogs of a cyclic peptide, cyclo[EKTOVNOGN], AFPep, that has anti-estrotrophic activity. The analogs of the invention include peptides and peptidomimetics that inhibit estrogen receptor-dependent cell proliferation. The compounds of the invention are useful for treating cell proliferative disorders or physiological conditions characterized by undesirable or unwanted estrogen induced cell proliferation, including breast cancer.

03-07-2013

20120109197

FACET DEVICE AND METHOD - A spine prosthesis is provided and in particular, related to the facet joint of a spine. A spinal implant comprises a facet prosthesis including an insert to be positioned within a joint capsule between facets of a zygapophyseal joint. The insert may comprise a member having two opposing facet interfacing portions. A facet prosthesis exerts a distraction force between facets of a facet joint and may comprise a curable material to be injected into the facet joint. A facet prosthesis may also comprise a pair of magnets, each magnet coupled to a facet and oriented with like poles facing each other to provide a distracting force away from each other. A spine implant may also include an insert to be positioned within the joint capsule, a securing member comprising an elongate portion extending through part of a facet, and an anchor to anchor the securing member to the facet.

05-03-2012

20110217264

METHODS AND COMPOSITIONS FOR DELIVERY OF EXOGENOUS FACTORS TO NERVIOUS SYSTEM SITES - The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems.

09-08-2011

20110104104

BLOCKAGE OF INTERFERON-GAMMA FOR PREVENTION OF POLYMICROBIAL SYNERGY - The present invention is directed to methods for treating a viral respiratory infection in a subject, preventing polymicrobial synergy in a subject, or preventing a bacterial infection in a subject. These methods include selecting a subject with a viral respiratory infection, a subject susceptible to polymicrobial synergy, or a subject susceptible to bacterial infection, respectively. In each case a therapeutic agent that inhibits interferon-gamma (IFNγ) is provided and administered to the selected subject under conditions effective to treat the viral respiratory infection, to prevent polymicrobial synergy, or to prevent a bacterial infection, respectively.

COMPOSITIONS AND METHODS FOR INHIBITING OR REVERSING FIBROTIC DISORDERS - The present invention provides compositions and methods for inhibiting or reversing fibrotic disorders by administering a Hic-5 antagonist to a mammal in need thereof. The invention also includes methods for screening compounds to identify Hic-5 antagonists useful in inhibiting or reversing fibrotic disorders.

11-18-2010

20100021422

METHODS AND COMPOSITIONS FOR DELIVERY OF EXOGENOUS FACTORS TO NERVOUS SYSTEM SITES - The present invention relates to treatment methods and methods for sustained delivery of one or more exogenous factors to desired nervous system sites. In certain embodiments, the invention relates to the use of biodegradable microspheres to deliver exogenous factors, such as the morphogenic factor, sonic hedgehog (Shh), to the site of spinal cord injury. In certain embodiments, the Shh-releasing microspheres are administered together with stem cells, which may be spinal cord neural stem cells. In certain embodiments, the invention relates to regrowth of neural cells in both the central and peripheral nervous systems.

PERFORMING DATA ANALYSIS ON CLINICAL DATA - Reference intervals are established and/or validated based on existing clinical data and exclusion criteria, such as diagnosis coding. A Reference Interval Test Engine is designed to statistically analyze large volumes of existing clinical lab test results to establish and evaluate reference intervals for specific population subgroups and/or to provide other applications.